Regulus Therapeutics (NASDAQ:RGLS – Get Free Report)'s stock had its "buy" rating reissued by analysts at HC Wainwright in a research report issued to clients and investors on Tuesday, Benzinga reports. They currently have a $10.00 price objective on the biopharmaceutical company's stock.
Other…
